Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide (Q47381999)
Jump to navigation
Jump to search
scientific article published on 8 April 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide |
scientific article published on 8 April 2011 |
Statements
1 reference
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide (English)
1 reference
Thomas L Seck
1 reference
Samuel S Engel
1 reference
Debora E Williams-Herman
1 reference
Christine McCrary Sisk
1 reference
Gregory T Golm
1 reference
Hongwei Wang
1 reference
Keith D Kaufman
1 reference
Barry J Goldstein
1 reference
8 April 2011
1 reference
93
1 reference
1
1 reference
e15-7
1 reference